372489-01-5

Upstream product

• 269070-79-3 2-adamantan-1-ylmethyl-5-phenyl-1H-pyrrole-3-carboxylic acid 
• 152699-63-3 5-Amino-isophthalic acid dibenzyl ester 
• 70-11-1 α-bromoacetophenone 
• 33566-14-2 4-adamantan-1-yl-3-oxobutyric acid ethyl ester 
• 269070-77-1 4-Adamantan-1-yl-3-oxo-2-(2-oxo-2-phenyl-ethyl)-butyric Acid Ethyl Ester 
• 269070-78-2 2-adamantan-1-ylmethyl-5-phenyl-1H-pyrrole-3-carboxylic acid ethyl ester 
• 1026901-73-4 2-adamantan-1-ylmethyl-5-phenyl-1H-pyrrole-3-carbonyl chloride 

Downstream Products

• 269067-65-4 2-Cycloheptylmethyl-5-naphthalen-2-yl-1H-pyrrole-3-carboxylic Acid [3-(1H-tetrazol-5-yl)-phenyl]-amide 
• 269070-81-7 2-Adamantan-1-ylmethyl-5-phenyl-1H-pyrrole-3-carboxylic Acid [3,5-bis-(1-pivaloyloxymethyl-1H-tetrazol-5-yl)-phenyl]-amide 

Relevant academic research and scientific papers

Scaffold hopping with molecular field points: Identification of a cholecystokinin-2 (CCK2) receptor pharmacophore and its use in the design of a prototypical series of pyrrole- and imidazole-based CCK2 antagonists

A new molecular modeling approach has been used to derive a pharmacophore of the potent and selective cholecystokinin-2 (CCK2) receptor antagonist 5 (JB93182), based on features shared with two related series. The technique uses "field points"

Gastrin and cholecystokinin receptor ligands

Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently ═N—, —N(R5)—═CH—, —S— or —O—. n is from 1 to 4; R1is H or C1to C1